on January 22, 2004
Published online before print January 22, 2004, doi: 10.1161/01.STR.0000109767.11426.17
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 12, 2003
From the Department of Neurology (D.K., B.K., A.S., D.W., J.K., R.M., K.A., J.G., J.S., C.M., J.B.), University of Cincinnati College of Medicine, the Neuroscience Institute; Department of Emergency Medicine (A.P., E.J.), University of Cincinnati College of Medicine; and Department of Environmental Health (R.S.), University of Cincinnati, Cincinnati, Ohio. * To whom correspondence should be addressed. E-mail: dawn.kleindorfer{at}uc.edu.
Background and Purpose--Acute ischemic stroke patients are infrequently treated with recombinant tissue plasminogen activator (rtPA). We present unique population-based data regarding the eligibility of ischemic stroke patients for rtPA treatment. Methods--All ischemic strokes presenting to an emergency department (ED) within a biracial population of 1.3 million were identified. The patient was considered eligible for rtPA on the basis of exclusion criteria from the National Institute of Neurological Disorders and Stroke rtPA trial. Results--Of 2308 ischemic strokes, 1849 presented to an ED. Only 22% of all ischemic strokes in the population arrived in the ED in <3 hours from symptom onset; of these, 209 (51%) were ineligible for rtPA on the basis of mild stroke severity, medical and surgical history, or blood tests. Conclusions--In our population in 1993 to 1994, 8% of all ischemic stroke patients presented to an ED within 3 hours and met other eligibility criteria for rtPA. Even if time were not an exclusion for rtPA, only 29% of all ischemic strokes in our population would have otherwise been eligible for rtPA.
Accepted on October 1, 2003
Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke. A Population-Based Study
Dawn Kleindorfer MD*;
Key words: eligibility determination • emergency treatment • stroke, acute • stroke, ischemic • tissue plasminogen activator
This article has been cited by other articles:
 |
|
 |
|
  S. Martin-Schild, H. Hallevi, K. C. Albright, A. M. Khaja, A. D. Barreto, N. R. Gonzales, J. C. Grotta, and S. I. Savitz Aggressive Blood Pressure-Lowering Treatment Before Intravenous Tissue Plasminogen Activator Therapy in Acute Ischemic Stroke Arch Neurol, September 1, 2008; 65(9): 1174 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M O McCarron, M Armstrong, and P McCarron Potential for quality improvement of acute stroke management in a district general hospital Emerg. Med. J., May 1, 2008; 25(5): 270 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Khatri, R. A. Taylor, V. Palumbo, V. Rajajee, J. M. Katz, J. A. Chalela, A. Geers, J. Haymore, D. M. Kolansky, S. E. Kasner, et al. The safety and efficacy of thrombolysis for strokes after cardiac catheterization. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 906 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kobayashi, M. Skowronska, T. Litwin, and A. Czlonkowska Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated Emerg. Med. J., February 1, 2007; 24(2): 96 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Rajajee, C. Kidwell, S. Starkman, B. Ovbiagele, J. R. Alger, P. Villablanca, F. Vinuela, G. Duckwiler, R. Jahan, A. Fredieu, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology, September 26, 2006; 67(6): 980 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. I. Gropen, P. J. Gagliano, C. A. Blake, R. L. Sacco, T. Kwiatkowski, N. J. Richmond, D. Leifer, R. Libman, S. Azhar, M. B. Daley, et al. Quality improvement in acute stroke: The New York State Stroke Center Designation Project. Neurology, July 11, 2006; 67(1): 88 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Z. Bambauer, S. C. Johnston, D. E. Bambauer, and J. A. Zivin Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol, May 1, 2006; 63(5): 661 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K D Hellier, J L Hampton, J V Guadagno, N P Higgins, N M Antoun, D J Day, J H Gillard, E A Warburton, and J-C Baron Perfusion CT helps decision making for thrombolysis when there is no clear time of onset. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 417 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Z. Deng, M. J. Reeves, B. S. Jacobs, G. L. Birbeck, R. U. Kothari, S. L. Hickenbottom, A. J. Mullard, S. Wehner, K. Maddox, A. Majid, et al. IV tissue plasminogen activator use in acute stroke: Experience from a statewide registry Neurology, February 14, 2006; 66(3): 306 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Schestatsky, P. D. Picon, D. O. Kleindorfer, P. Khatri, I. Katzan, and D. Cocho Reasons for exclusion from thrombolytic therapy following acute ischemic stroke Neurology, December 13, 2005; 65(11): 1844 - 1844. [Full Text] [PDF]
|
|
|
|
 |
|
 Part 9: Adult Stroke Circulation, December 13, 2005; 112(24_suppl): IV-111 - IV-120. [Full Text] [PDF]
|
|
|
|
|
|
L. H. Schwamm, A. Pancioli, J. E. Acker III, L. B. Goldstein, R. D. Zorowitz, T. J. Shephard, P. Moyer, M. Gorman, S. C. Johnston, P. W. Duncan, et al. Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association's Task Force on the Development of Stroke Systems Circulation, March 1, 2005; 111(8): 1078 - 1091. [Full Text] [PDF]
|
|
|
|
 |
|
 P. U. Heuschmann, P. L. Kolominsky-Rabas, J. Roether, B. Misselwitz, K. Lowitzsch, J. Heidrich, P. Hermanek, C. Leffmann, M. Sitzer, M. Biegler, et al. Predictors of In-Hospital Mortality in Patients With Acute Ischemic Stroke Treated With Thrombolytic Therapy JAMA, October 20, 2004; 292(15): 1831 - 1838. [Abstract] [Full Text] [PDF]
|
|